

Supplementary 1: Reference biological and biosimilar medications approved by the Iraqi Ministry of Health

Reference medications	Company	Biosimilar medications	Company	Indicating areas
Adalimumab (Humira)	Abbvie	Adalimumab (Amgevita)	Amgen	Rheumatology, Gastroenterology and Hepatology.
Aflibercept (Eylea)	Bayer	N/A		Ophthalmology
Agalsidase beta (Fabrazyme)	Genzyme	N/A		Nephrology, Neurology, Gastroenterology
Antithymocyte globulin (Atgam)	Pfizer	N/A		Nephrology
Basiliximab (Simulect)	NOVARTIS	N/A		Nephrology
Bevacizumab (Avastin)	Genentech	Bevacizumab (Stivant)	Aryogen	Oncology, ophthalmology
Bortezomib (Alvocade)	Nano Fanavaran			Oncology (Hematology)
Etanercept (Enbrel)	Pfizer	N/A		Rheumatology, Dermatology
		Filgrastim (Zarxio)	Sandoz	Oncology
		Filgrastim (Nivestim)	Hospira	
Gaisulfate (Naglazym)	Biomarin pharma	N/A		Rheumatology
Glucagon (GlucaGen)	Nova Nordisk	N/A		Endocrinology
Heparin (Heparin LEO)	LEO Pharma			Internal Medicine
Human Erythropoietin (alfa rh Epo)(recomb) (Eprex)	Janssen-Cilag	Human erythropoietin (Alfa RH Epo) (Binocrit)	Sandoz	Nephrology
		Epoetin Alfa - epbx (Retacrit)	Pfizer	
		Recombinant human erythropoietin (Koromon)	HANKOOK KORUS Pharm CO. LTD	
Human Coagulation Factor VIII (Haemate P)	CSL Behring	Human Coagulation Factor VIII (Wilate)	Octapharma	Hematology
Human Coagulation Factor IX (Rixubis)	Baxalta	N/A		Hematology
Human Coagulation Factor XIII (Fibrogammin)	CSL Behring	N/A		Hematology
Human normal immunoglobulin (Kiovig)	Baxalta	Human normal immunoglobulin (I.V Globulin SN)	Green Cross Corp	
Infliximab (remicade)	Schering - plough	Infliximab (remsima)	HikMA	Rheumatology, gastroenterology and Hepatology.
Interferon Beta-1a (Rebif)	Merck	Interferon Beta-1a (Avonex)	Biogen	Neurology
		Interferon beta -1 a (recomb) (ReciGen)	Cinnagen	

		Interferon beta -1 a (Cinnovex)	Cinnagen	
Interferon Beta-1b (recomb)(Betaferon)	Bayer	N/A		
Idursulfase (Elaprase)	Takeda	N/A		Gastroenterology, Neurology
Natalizumab (TYSABRI®)	Biogen	N/A		Neurology
Omaliuzumab (Xolair)	Novartis	N/A		Dermatology
Palivizumab (SYNAGIS)	Sobi	N/A		Pediatrician
Ranibizumab (Lucentis)	Genentech	N/A		Ophthalmology
		Recombinant activated human coagulation Factor VII (AryoSeven)	AryoGen	Hematology
		Recombinant activated coagulation Factor VII (NovoSeven)	Novo Nordisk	
Recombinant antihemophilic Factor VIII (Xyntha)	Pfizer	Recombinant antihemophilic Factor VIII (NovoEight)	Novo Nordisk	
Recombinant human-choriogonadotropin alfa (Ovitrelle)	Merck Serono			Fertility/Gynecology
Rituximab (Mabthera)	Roche	Rituximab (zytux)	Aryogen	Rheumatology, Dermatology, oncology, nephrology, neurology
Somatropin (Omnitrope)	Sandoz	Somatropin (Norditropin)	Novo Nordisk	Pediatrician
Trastuzumab (Herceptin)	Roche	Trastuzumab (Aryotrust)	Aryogen	Oncology
Ustekinumab (STELARA)	Janssen	N/A		Gastroenterology and Hepatology.
Velaglucerase alpha (VPRIV)	Takeda			Pediatrician

Last updated April 1, 2021. N/A=not approved yet. Some medicines were approved after all interviews completed.
Source: The IqPhvC, Iraqi Ministry of Health